FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Boston Hospitals To Test Cystic Fibrosis Drug On Severely Ill Coronavirus Patients
BOSTON (CBS) — Harvard University researchers are working with two Boston hospitals to try a new way to help the sickest coronavirus patients. Boston Children’s Hospital and Brigham and Women’s Hospital will test a drug approved by the FDA to treat people with cystic fibrosis on those experiencing severe COVID-19 pneumonia and respiratory failure. The drug is called Dornase alfa, also known as DNase 1 or Pulmozyme, and it works to prevent lung infections by breaking up thick mucus. That may make oxygen easier to deliver via ventilator, researchers say. There’s also hope that the drug might break up ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 7, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Syndicated CBSN Boston Syndicated Local Boston Children's Hospital Brigham and Women's Hospital Coronavirus Harvard University Source Type: news

Randomized study for treatment of COVID pneumonia uses cystic fibrosis drug dornase alfa
(Boston Children's Hospital) Researchers at Boston Children's Hospital and Brigham and Women's Hospital have launched a randomized, placebo-controlled clinical trial of dornase alfa (Pulmozyme) in patients with severe COVID-19 pneumonia and respiratory failure requiring mechanical ventilation. The study aims to enroll 60 adults and children (over age 3) admitted to intensive care units. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 28, 2020 Category: International Medicine & Public Health Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care ...
Source: Roche Investor Update - March 3, 2020 Category: Pharmaceuticals Source Type: news

dornase alpha (Pulmozyme)
Title: dornase alpha (Pulmozyme)Category: MedicationsCreated: 12/14/2000 12:00:00 AMLast Editorial Review: 10/23/2019 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - October 23, 2019 Category: Respiratory Medicine Source Type: news

Pulmozyme (Dornase alfa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 21, 2017 Category: Drugs & Pharmacology Source Type: news